Ovid Therapeutics Inc
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
OVID$2.80-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
Condensed Consolidated Statements of Stockholders’ Equity (unaudited)
| (in thousands, except shares) · Series AConvertiblePreferred Stock · Common Stock · AdditionalPaid-In Capital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · Total | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount | ||||||||||||
| Balance, December 31, 2024 | 1,250 | $— | 71,009,866 | $71 | $372,489 | $(35) | $(304,299) | $68,226 | ||||
| Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan | — | — | 99,648 | — | 13 | — | — | 13 | ||||
| Stock-based compensation expense | — | — | — | — | 1,284 | — | — | 1,284 | ||||
| Other comprehensive loss | — | — | — | — | — | (12) | — | (12) | ||||
| Net loss | — | — | — | — | — | — | (10,235) | (10,235) | ||||
| Balance, March 31, 2025 | 1,250 | $— | 71,109,514 | $71 | $373,786 | $(47) | $(314,533) | $59,276 | ||||
| (in thousands, except shares) | Series AConvertiblePreferred Stock | Common Stock | AdditionalPaid-In Capital | AccumulatedOtherComprehensive (Loss) Income | Accumulated Deficit | Total | ||||||
| Shares · Amount · Shares · Amount | ||||||||||||
| Balance, December 31, 2023 | 1,250 | $— | 70,691,992 | $71 | $365,591 | $1 | $(277,866) | $87,797 | ||||
| Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan | — | — | 91,969 | — | 228 | — | — | 228 | ||||
| Stock-based compensation expense | — | — | — | — | 1,968 | — | — | 1,968 | ||||
| Other comprehensive income | — | — | — | — | — | (20) | — | (20) | ||||
| Net loss | — | — | — | — | — | — | (11,694) | (11,694) | ||||
| Balance, March 31, 2024 | 1,250 | $— | 70,783,961 | $71 | $367,787 | $(19) | $(289,560) | $78,279 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.